Regeneron Pharmaceuticals, Inc. (REGN) $761.85
Regeneron Pharmaceuticals (REGN) currently hovers just below its 50-day moving average, presenting a critical juncture for investors. This biotech giant, known for its robust pipeline, now faces a technical test that will dictate its near-term trajectory.
52-wk High $821.11
📌 Investment Snapshot
- REGN trades at $761.85, commanding an $80.5B market cap with a P/E of 18.38x.
- Latest quarter revenue hit $3.88B, driving EPS of $7.86, supported by $1.2B in buybacks.
- The stock is currently testing its 50-day SMA, a pivotal technical level for near-term direction.
- Analysts maintain a 'Buy' consensus with a $872.70 target, implying 14.55% upside.
Regeneron currently trades at $761.85, just below its 50-day SMA, signaling a critical technical test. While the company demonstrates strong fundamentals and analyst support, the RSI of 55.9 suggests it is not yet oversold enough for a high-conviction entry.
| 📍 Entry Zone | $740.00 or below | 🛑 Stop-Loss | $715.00 |
| 📋 Adjust If | REGN closes above $770.00 with 1.5x average volume, confirming a breakout. | ||
The Investment Case — Why Now?
Over the past 60-90 days, Regeneron has shown resilience, with its stock consolidating near recent highs despite broader market fluctuations. The latest earnings report confirmed robust revenue growth and a commitment to shareholder returns through significant buybacks, underpinning its fundamental strength. This stability, however, now faces a technical challenge as the stock attempts to reclaim its short-term moving averages.
The primary risk to this thesis lies in potential pipeline setbacks or unexpected competition for key drugs like Eylea or Dupixent. A significant clinical trial failure or a new market entrant could rapidly erode investor confidence, pushing the stock into falling knife territory. Investors must monitor upcoming trial readouts and competitive landscape shifts closely.
🤔 Given REGN's strong fundamentals but current technical indecision, are you prioritizing long-term growth prospects or waiting for a clearer technical entry signal?
🏢 Company Overview
| Detail | Value |
|---|---|
| Company | Regeneron Pharmaceuticals, Inc. |
| Ticker / Exchange | REGN / NASDAQ |
| Sector / Industry | Healthcare / Biotechnology |
| CEO | Leonard S. Schleifer, M.D., Ph.D. |
| Founded / HQ | 1988 / Tarrytown, New York |
📈 Price Action & Technicals
Inside VA
A sell-side sweep at $771.23 on April 1st suggests institutional selling pressure near recent highs, while prior buy-side sweeps at $741.90 and $746.66 indicate demand at lower levels.
REGN currently trades at $761.85, positioned just below its 50-day SMA of $765.13, which acts as immediate resistance. The stock remains well above its 200-day SMA of $661.49, confirming a longer-term bullish trend despite recent consolidation. This setup suggests a pivotal moment where a decisive move above the 50-day SMA could signal renewed upward momentum.
The RSI at 55.9 sits in neutral territory, offering no immediate overbought or oversold signals. While the MACD shows a negative value (-1.73) but is above its signal line (-4.76), it suggests waning bearish momentum rather than a strong bullish reversal. The ADX at 21.6, with -DI (26.2) slightly above +DI (22.0), indicates a weak bearish trend in play, lacking strong directional conviction.
The Anchored VWAP from June 2025 at $644.01 sits significantly below the current price, confirming strong accumulation over the past year. The Volume Profile’s Point of Control (POC) at $567.43 and Value Area (VA) spanning $550.58 to $786.43 show the current price is within the upper bounds of the high-volume trading range. This suggests the stock is trading in an area where significant price discovery has occurred.
Volume today runs at 1.64x its 20-day average, indicating heightened activity as the stock tests key levels. The Bollinger Bands show the price near the upper band ($784.56), but the recent sell-side liquidity sweep at $771.23 suggests overhead supply. This divergence, with high volume but a recent sweep indicating selling, warrants caution.
🤔 Considering the conflicting signals from MACD (waning bearish momentum) and ADX (weak bearish trend), what technical indicator would you prioritize for confirmation of REGN's next major move?
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| REGN | Regeneron Pharmaceuticals | 18.38x |
| AMGN | Amgen Inc. | 19.5x |
| GILD | Gilead Sciences | 15.2x |
| BIIB | Biogen Inc. | 22.1x |
| S&P 500 | Index Average | 21.0x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q4 2025 | $3.88B | $7.86 | |
| Q3 2025 | $3.75B | $13.62 | |
| Q2 2025 | $3.68B | $12.81 | |
| Q1 2025 | $3.03B | $7.27 |
Regeneron generated $0.9B in Free Cash Flow in the latest quarter, demonstrating robust operational efficiency. The company actively returned capital to shareholders, executing $1.2B in buybacks, signaling confidence in its valuation and future prospects.
🚀 Growth Drivers — What Moves the Stock
- Eylea & Dupixent Continued Dominance 🟡 Priced In — Eylea, for eye diseases, and Dupixent, for inflammatory conditions, remain Regeneron’s flagship products, consistently driving significant revenue growth. Their broad indications and strong market penetration provide a stable revenue base and fuel further pipeline investment.
- Robust Pipeline Expansion 🟢 Upside Surprise — Regeneron boasts a deep and diverse pipeline, with multiple late-stage candidates across oncology, immunology, and rare diseases. Positive clinical trial readouts, particularly for novel mechanisms, represent significant upside potential beyond current market expectations.
- Strategic Partnerships & M&A 🟢 Upside Surprise — The company’s history of successful collaborations and strategic acquisitions enhances its R&D capabilities and market reach. Future partnerships or targeted M&A could accelerate market entry for new therapies and diversify revenue streams.
🤔 Given the established success of Eylea and Dupixent, how much weight should investors place on the speculative upside from Regeneron's pipeline versus its current market dominance?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Vanguard Group Inc | 9,075 |
| Blackrock Inc. | 8,741 |
| State Street Corporation | 4,660 |
| Dodge & Cox Inc. | 4,596 |
| JPMORGAN CHASE & CO | 3,940 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| RYAN ARTHUR F | Director | Mar 2, 2026 | Sale | 100 |
| ZOGHBI HUDA Y | Director | Feb 19, 2026 | Sale | 1,638 |
| PITOFSKY JASON | Officer | Feb 9, 2026 | Sale | 2,036 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 0.0% | 4.0 |
⚠ Key Risk Factors
~$5B impact
~$10B impact
~$7B impact
~$4B impact
🤔 Considering the inherent risks in biotech, how do you weigh Regeneron's diversified pipeline against the potential impact of a single major clinical setback or increased competition for its flagship products?
🎯 Guidance & Wall Street View
Regeneron’s management has consistently reiterated its focus on advancing its deep pipeline and maximizing the lifecycle of its established blockbusters. They project continued revenue growth driven by key products and anticipate several pivotal clinical readouts in the coming year.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $1057.0 | $872.70 | $730.0 | 28 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| Truist Securities | Buy | $870 | Mar 2026 | Maintains |
| Barclays | Overweight | $900 | Mar 2026 | Initiates |
| RBC Capital | Sector Perform | $820 | Mar 2026 | Maintains |
| Guggenheim | Buy | $920 | Feb 2026 | Maintains |
| JP Morgan | Overweight | $880 | Feb 2026 | Maintains |
The analyst community holds a strong 'Buy' consensus on REGN, with a mean target of $872.70 suggesting a healthy 14.55% upside. This collective optimism underscores confidence in the company’s fundamental strength and future growth trajectory.
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Successful late-stage pipeline readouts for new indications or novel therapies could significantly expand market opportunities and drive substantial revenue growth beyond current projections.
- Stronger-than-expected market share gains for Dupixent in new geographies or approved indications, combined with effective defense against biosimilar competition for Eylea, would boost top-line performance.
📊 Base Case
Our base case assumes continued steady growth from Eylea and Dupixent, coupled with moderate success from pipeline candidates. This scenario factors in ongoing R&D investment and a stable competitive landscape, leading to a fair value reflecting current analyst consensus.
🐻 Bear Case
- Major clinical trial failures or unexpected safety concerns for pipeline assets could severely impact future growth prospects and investor sentiment.
- Aggressive pricing pressure from competitors or regulatory bodies, particularly for key revenue drivers, could erode profit margins and lead to downward revisions in earnings forecasts.
🎯 Investor Action Plan — By Profile
Swing traders should avoid REGN for now due to mixed technical signals and the stock trading below its 50-day SMA. A clear break above $770 with sustained volume is required for a short-term long entry, targeting $785 with a tight stop at $755.
Position investors should stay on the sidelines, awaiting a pullback to the $740 support zone or a confirmed breakout above $770. Accumulate gradually in the $720-$740 range, with a long-term stop below $715 if the fundamental thesis remains intact.
Long-term investors already holding REGN should maintain their positions, as the fundamental growth thesis remains robust. Consider adding to positions on significant pullbacks towards the 200-day SMA ($661.49) if the company’s pipeline continues to deliver.
❓ Investor FAQ — People Also Ask
Q: What are the key technical levels to watch for REGN’s next move?
Regeneron faces immediate resistance at its 50-day SMA of $765.13 and the recent sell-side liquidity sweep at $771.23. Key support lies around the $740 mark, bolstered by recent buy-side sweeps, and further down at the Bollinger Band lower bound of $724.85. A decisive break of these levels will dictate short-term direction.
Q: How does Regeneron’s valuation compare to its peers?
Regeneron’s P/E ratio of 18.38x positions it favorably against the S&P 500 average of 21.0x and broadly in line with or slightly below some large-cap biotech peers. This suggests the stock is not excessively valued, especially considering its strong product portfolio and pipeline.
Q: What does the institutional activity tell us about REGN?
Major institutions like Vanguard and Blackrock hold significant stakes, indicating long-term confidence in Regeneron. While recent insider transactions show some selling, the overall institutional backing suggests a stable investor base, which is a positive sign for stability.
📊 Want to check the current price action yourself?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results.
All active positions and their real-time performance are tracked on our Investment Log.
#REGN #Regeneron #BiotechStocks #HealthcareInvesting #StockAnalysis #NYSE #NASDAQ #Veqtio